Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)

• Published in: The Journal of biological chemistry Vol. 293; no. 37; pp. 14328 - 14341
• Main Authors: Kong, Yifan, Cheng, Lijun, Mao, Fengyi, Zhang, Zhuangzhuang, Zhang, Yanquan, Farah, Elia, Bosler, Jacob, Bai, Yunfeng, Ahmad, Nihal, Kuang, Shihuan, Li, Lang, Liu, Xiaoqi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14-09-2018; American Society for Biochemistry and Molecular Biology
• Subjects: Animals; Cell Biology; Cell Line, Tumor; Cholesterol - biosynthesis; Drug Resistance, Neoplasm; Humans; Hydroxymethylglutaryl CoA Reductases - genetics; Hydroxymethylglutaryl CoA Reductases - metabolism; Male; Mice; Mice, Nude; Phenylthiohydantoin - administration & dosage; Phenylthiohydantoin - analogs & derivatives; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - enzymology; Prostatic Neoplasms, Castration-Resistant - genetics; Prostatic Neoplasms, Castration-Resistant - metabolism; Receptors, Androgen - genetics; Receptors, Androgen - metabolism; prostate cancer; drug resistance; hormone receptor; cholesterol regulation; tumor therapy
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.RA118.004442

Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved for the management of castration-resistant prostate cancer (CRPC). Although patients can benefit from enzalutamide at the beginning of this therapy, acquired enzalutamide resistance usually occurs within a short period. This motivated us to investigate the mechanism involved and possible approaches for overcoming enzalutamide resistance in CRPC. In the present study, we found that 3-hydroxy-3-methyl-glutaryl–CoA reductase (HMGCR), a crucial enzyme in the mevalonate pathway for sterol biosynthesis, is elevated in enzalutamide-resistant prostate cancer cell lines. HMGCR knockdown could resensitize these cells to the drug, and HMGCR overexpression conferred resistance to it, suggesting that aberrant HMGCR expression is an important enzalutamide-resistance mechanism in prostate cancer cells. Furthermore, enzalutamide-resistant prostate cancer cells were more sensitive to statins, which are HMGCR inhibitors. Of note, a combination of simvastatin and enzalutamide significantly inhibited the growth of enzalutamide-resistant prostate cancer cells in vitro and tumors in vivo. Mechanistically, simvastatin decreased protein levels of the androgen receptor (AR), which was further reduced in combination with enzalutamide. We observed that the decrease in AR may occur through simvastatin-mediated inhibition of the mTOR pathway, whose activation was associated with increased HMGCR and AR expression. These results indicate that simvastatin enhances the efficacy of enzalutamide-based therapy, highlighting the therapeutic potential of statins to overcome enzalutamide resistance in CRPC.